A comprehensive look at explicit screening tools for potentially inappropriate medication: A systematic scoping review
- PMID: 35226786
- DOI: 10.1111/ajag.13046
A comprehensive look at explicit screening tools for potentially inappropriate medication: A systematic scoping review
Abstract
Objective: To map explicit screening tools to identify potentially inappropriate medication (PIMs), and the characteristics and limitations of these tools. Including PIMs-interactions, therapeutic alternatives and the clinical management of PIMs.
Methods: A systematic scoping review was conducted in PubMed and Scopus (until May 2021). The number of PIMs listed as essential drugs was identified in Model List of Essential Medicines by the World Health Organization (WHO) and National List of Essential Medicines (Brazil). In addition to reporting the therapeutic alternatives and clinical management proposed by explicit screening tools to identify PIMs, we suggested our own alternatives for the PIMs most frequently reported.
Results: Fifty-eight tools reported 614 PIMs and 747 PIMs-interactions. Limited overlap between the tools was observed: 123 (69.1%) of 178 therapeutic alternatives proposed by the tools were considered inappropriate by other tools, and 222 (36.1%) of the 614 PIMs identified were named as being inappropriate only once. Only 21 tools were developed by a Delphi panel technique associated with systematic review. The PIMs listed as essential medication in Brazil and by the WHO were 30.6% and 23.3% of the total reported, respectively. For the most-cited PIMs, such as non-steroidal anti-inflammatory drugs, tricyclic antidepressants and benzodiazepines, we suggested the use of non-opioid and opioid analgesics; agomelatine, bupropion or moclobemide; and melatonin, respectively.
Conclusions: The next stages in the development of explicit screening tools to identify PIMs include achieving more consensus between them and improving their applicability across countries. Further, it is recommended that tools include PIMs risks and advice on therapeutic alternatives.
Keywords: aged; drug contraindication; drug-related side effects and adverse reactions; inappropriate prescribing; potentially inappropriate medication list.
© 2022 AJA Inc.
References
-
- O'Mahony D, Gallagher P, Lavan A. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clinical Interventions in Aging. 2016;11:857-866. doi:10.2147/cia.s80280
-
- O Riordan D, Aubert CE, Walsh KA, et al. Prevalence of potentially inappropriate prescribing in a subpopulation of older European clinical trial participants: a cross-sectional study. BMJ Open. 2018;8(3):e019003. doi:10.1136/bmjopen-2017-019003
-
- Shade MY, Berger AM, Chaperon C, Haynatzki G, Sobeski L, Yates B. Factors associated with potentially inappropriate medication use in rural, community-dwelling older adults. J Gerontol Nurs. 2017;43(9):21-30. doi:10.3928/00989134-20170406-01
-
- Varallo FR, Costa MA, Mastroianni PC. Potenciais interações medicamentosas responsáveis por internações hospitalares. Rev Ciencias Farm Basica E Apl. 2013;34(1):79-85. https://hdl.handle.net/11449/107431
-
- O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: need for new criteria. Age Ageing. 2008;37(2):138-141. doi:10.1093/ageing/afm189
Publication types
MeSH terms
Grants and funding
- 459461/2014-1/Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Código de financiamento 001
- 2018/07501-9/Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- 2019/01565-8/Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
LinkOut - more resources
Full Text Sources